Shareholder

RITE AID CORPORATION (NYSE: RAD) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Rite Aid Corporation (NYSE: RAD)

Retrieved on: 
Wednesday, November 30, 2022
Growth, Labour government, PBM, Rite, Shareholder, Court, RAD, State, The Legal 500, Investment, District court, News, NYSE, Pharmacy, Rite Aid, Forest Law Enforcement and Governance Program, Advertising, Security (finance), Pharmaceutical industry, Elixir, Dan Donigan

NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Rite Aid Corporation (“Rite Aid” or the “Company”) (NYSE: RAD) between April 14, 2022 and September 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Rite Aid Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Rite Aid, through its subsidiaries, operates a chain of retail drugstores in the U.S.
  • If you purchased Rite Aid securities, and/or would like to discuss your legal rights and options please visit Rite Aid Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

Retrieved on: 
Tuesday, November 29, 2022
Institutional Shareholder Services, Internet, DFC (cipher), SAN, Proxy, Special, Elias Neocleous & Co LLC, Glass Lewis, Telephone, Therapy, Biotechnology, Patient, CDTX, ISS, PST, Pharmaceutical industry, Shareholder

We appreciate the recommendation of two leading independent proxy advisory firms advising our stockholders to vote in favor of the proposed reverse stock split, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • We appreciate the recommendation of two leading independent proxy advisory firms advising our stockholders to vote in favor of the proposed reverse stock split, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • ISS and Glass Lewis are independent proxy advisory firms and do not have any business relationship with Cidara.
  • Stockholders of record at the close of business on November 8, 2022 can vote by proxy or online during the Special Meeting.
  • Vote by proxy card: Complete, sign and date the proxy card and return it promptly in the envelope provided.

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

Retrieved on: 
Tuesday, November 29, 2022
Galectin, Food, Liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Fatty liver disease, Shareholder, NASH, Cirrhosis, Cancer, Therapy, GALT, Chronic liver disease, Pharmaceutical industry

NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m.

Key Points: 
  • NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m.
  • Please log in approximately 10 minutes before the event to ensure a timely connection.
  • Galectin Therapeuticsis dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
  • Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.

STORE Capital Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by GIC and Oak Street

Retrieved on: 
Tuesday, November 29, 2022
Commercial Building & Real Estate, Construction & Property, REIT, Special-purpose acquisition company, Attention, Special, Glass, REIT, Risk, Oak Street, ISS, GIC, Security (finance), NYSE, Investment, Acquisition, Real estate, Holding company, Shareholder

The Company's Board of Directors recommends that you vote FOR the proposed merger.

Key Points: 
  • The Company's Board of Directors recommends that you vote FOR the proposed merger.
  • All stockholders of record as of the close of business on October 24, 2022 are entitled to vote at the Special Meeting.
  • The Companys stockholders are reminded that their vote is extremely important, no matter how many shares they own.
  • To follow the recommendations of ISS, Glass Lewis and the Company's Board of Directors, stockholders should vote FOR the proposed merger prior to December 9th, 2022.

Kineta to Participate in JMP Securities Hematology and Oncology Summit

Retrieved on: 
Tuesday, November 29, 2022
Proxy, Lymphatic system, Proxy statement, Head, Nature, Immunoglobulin G, NSCLC, Lung, Antibody, Immunosuppression, VISTA, IND, Food and Drug Administration Amendments Act of 2007, Therapy, Immunotherapy, Society, Tumor microenvironment, Prospectus, Register, Registration statement, Annual general meeting, Drug development, ESMO, Cancer, European Society for Medical Oncology, Sale, Neck, SITC, Form, Congress, Society for Immunotherapy of Cancer, Vaccine, Security (finance), Yuman–Cochimí languages, Janssen, Shareholder, Kineta

Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients lives.

Key Points: 
  • Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients lives.
  • Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy.
  • For more information on Kineta, please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .
  • No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Catheter Precision’s VIVO™ Systems Used in More Than 20 Procedures at NYU Langone Hospital

Retrieved on: 
Tuesday, November 29, 2022
Medical Devices, Health, Surgery, General Health, Cardiology, Biotechnology, Special, Disease, Tripura Merger Agreement, AS, Common stock, Definitive, Arrhythmia, Security (finance), Cardiac electrophysiology, VIVO, Financial statement, Communication, NYSE American, Catheter, Workflow, Sumathi Best Television Current Reporting Award, WILL, Common, CE, FDA, COVID-19, Growth, ALL, COMMUNICATION, Private, RA, Anatomy, Physician, NYSE, Electrophysiology, Amigo, AND, Exhibit, NYU Langone Health, FORM, Public Sector Net Cash Requirement, Public–Private Investment Program for Legacy Assets, NYU Langone Hospital — Long Island, Sale, 8-K, Business, OR, Form 10-K, Plan, Medical device, Medical imaging, Holding company, Mergers and acquisitions, Shareholder

Catheter Precision, Inc. , a medical device and technology company focused on cardiac electrophysiology, announces the completion of more than 20 procedures at NYU Langone Hospital utilizing the VIVO System that enables physicians to identify the origin of arrhythmias pre-procedure.

Key Points: 
  • Catheter Precision, Inc. , a medical device and technology company focused on cardiac electrophysiology, announces the completion of more than 20 procedures at NYU Langone Hospital utilizing the VIVO System that enables physicians to identify the origin of arrhythmias pre-procedure.
  • Completing the first 20 cases with VIVO at NYU Langone hospital is another milestone demonstrating clinical acceptance of our VIVO system, said David Jenkins, Catheter Precision CEO.
  • Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.
  • Under the terms of the definitive merger agreement with Ra Medical Systems, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in a stock-for-stock reverse merger transaction.

TC Energy provides growth outlook for 2023 and defines funding plan at Investor Day 2022

Retrieved on: 
Tuesday, November 29, 2022
Growth, EST, Environment, Coast, EBITDA, TSX, TC Energy, Natural gas, Erosion, Annual report, MD, WCSB, SEDAR, Webcast, TRP, NYSE, Carbon, MST, Hydrogen, TC, News, Shareholder, Safety, Renewable energy, Risk management

CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- News Release TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will host its annual Investor Day today.

Key Points: 
  • CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- News Release TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will host its annual Investor Day today.
  • We are reaffirming our long-term comparable EBITDA growth outlook of six per cent by 2026 and three to five per cent annual dividend growth rate.
  • We are introducing our 2023 comparable EBITDA outlook that we expect will be five to seven per cent higher than 2022.
  • The presentation materials will be available at 2022 Investor Day Toronto (tcenergy.com) at 7:00 a.m. EST (5:00 a.m. MST).

Leumi Continues to Deliver Strong Results - Net Income in the First Nine Months of 2022 reaches NIS 5.4 Billion ($1.5 Billion)

Retrieved on: 
Tuesday, November 29, 2022
Growth, NIS, HQ, Toyota Publica, Bank, Common equity, Sale, Shareholder, TASE, NPL, Valley Bank, Fossil fuel, Renewable energy, Airline, Lod, Q3, Bank Leumi, Credit

Net income in the first nine months of the year reached NIS 5.4 billion ($1.5 billion), compared to NIS 4.6 billion ($1.3 billion) in the corresponding period last year.

Key Points: 
  • Net income in the first nine months of the year reached NIS 5.4 billion ($1.5 billion), compared to NIS 4.6 billion ($1.3 billion) in the corresponding period last year.
  • > Finance incomein the first nine months of 2022, net of the results of Leumi USA, reached NIS 9.9 billion ($2.8 billion), compared to NIS 8.5 billion ($2.4 billion) in the corresponding period last year, a 16.5% increase.
  • > Shareholder's equityas at September 30, 2022 totaled NIS 48 billion ($14 billion), compared to NIS 41.8 billion ($12 billion) as at September 30, 2021.
  • > Deposits by the publicas at September 30, 2022 totaled NIS 546.7 billion ($154.3 billion), compared with NIS 478.8 billion ($135.1 billion) as at September 30, 2021 - a 14.2% increase.

VM HOTEL ACQUISITION CORP. ANNOUNCES APPROVAL OF EXTENSION, OPTION PLAN AND REDEMPTION AMOUNT

Retrieved on: 
Tuesday, November 29, 2022
TSX, Meeting, Part, Legislation, Delaware General Corporation Law, The Meeting, Suite, Extension, Delaware Corporate and Commercial Litigation Blog, Tax, Corporation, Redemption, Income Tax Act 2007, Shareholder, Income Tax Act, Brookfield Place, Acquisition, VMH, Security (finance), Risk management, Bay Street

Following the receipt of approval of the Shareholders, the board of directors approved the Extension, effective as of November 29, 2022.

Key Points: 
  • Following the receipt of approval of the Shareholders, the board of directors approved the Extension, effective as of November 29, 2022.
  • In connection with the Meeting, VMH provided Shareholders with the opportunity to deposit their Class A Restricted Voting Shares for redemption (the "Redemption").
  • 8,344,658 Class A Restricted Voting Shares were deposited for redemption in connection with the Extension.
  • About VM Hotel Acquisition Corp.
    VMH is a special purpose acquisition company incorporated under the laws of the Province of British Columbia for the purpose of effecting a qualifying acquisition within a specified period of time.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Rite Aid Corporation of Class Action Lawsuit and Upcoming Deadline – RAD

Retrieved on: 
Monday, November 28, 2022
Growth, LLP, Pomerantz, PBM, Complaint, Shareholder, Rite, Court, Ext, District court, NYSE, Pharmacy, News, Rite Aid, SEC Rule 10b-5, Forest Law Enforcement and Governance Program, Person, Pharmaceutical industry, Elixir

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rite Aid Corporation (Rite Aid or the Company) (NYSE: RAD) and certain of its officers.

Key Points: 
  • NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rite Aid Corporation (Rite Aid or the Company) (NYSE: RAD) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.